Sourced from:Direct from Manufacturer
Quick Summary
Anvimo 240mg Tablet
Last updated on 08 Aug 2026 | 06:05 AM (IST)
₹21559
MRP: ₹25752
(You Save ₹4193)
10 TABLET(s) IN A STRIP
Anvimo 240 mg Tablet is a prescription anticancer medicine used in the treatment of certain solid tumors as advised by an oncologist. It contains a targeted therapy that works by blocking specific pathways involved in tumor growth and spread. Anvimo is taken under strict medical supervision as part of a personalized oncology treatment plan.
Sourced from:Direct from Manufacturer
16% OFF
₹21559
MRP: ₹25,752.00
Inclusive of all taxes
16% Off
Dispatch: Today
Order In: 0h 0m 0s
0h 0m 0s
Order before timer ends to ensure your medicine is dispatched at...
Introduction to Anvimo 240mg Tablet
Anvimo 240mg Tablet is an antiviral medication containing letermovir as its active ingredient. It belongs to the pharmacological class of antiviral agents and is specifically classified under cytomegalovirus (CMV) DNA terminase inhibitors. Anvimo 240mg Tablet is primarily used to prevent cytomegalovirus (CMV) infection in patients who have recently undergone an allogeneic hematopoietic stem cell transplant (HSCT) and are at a higher risk of CMV reactivation.
Anvimo 240mg Tablet works by inhibiting the CMV DNA terminase complex, which is crucial for viral replication. It is typically prescribed for CMV-seropositive adult patients post-transplant to reduce the likelihood of viral complications. However, the medication is not a treatment for existing CMV infections.
Patients taking this medication should follow strict safety precautions. It is contraindicated in individuals with known hypersensitivity to letermovir or any of its excipients. Additionally, it is not recommended for use with certain medications due to serious drug interactions. Healthcare professionals advise caution in pregnant or breastfeeding women, individuals with liver impairment, and those consuming alcohol.
Uses of Anvimo 240mg Tablet
Anvimo 240mg Tablet is FDA-approved for the prevention of cytomegalovirus (CMV) infection in adult patients who:
- Have undergone allogeneic hematopoietic stem cell transplantation (HSCT)
- Are CMV-seropositive, meaning they have previously been exposed to the virus
This medication is used prophylactically and should not be used to treat an active CMV infection.
Therapeutic Effects of Anvimo 240mg Tablet
Anvimo 240mg Tablet functions by blocking the CMV DNA terminase complex, a key component required for viral replication. Unlike conventional antiviral drugs that target DNA polymerase, this medication disrupts viral DNA processing and packaging, ultimately preventing the virus from multiplying and spreading in the body.
By stopping CMV replication early in the process, this drug significantly lowers the risk of CMV disease in transplant recipients. The unique mechanism of action makes it highly effective while reducing the likelihood of cross-resistance seen with other CMV treatments. Due to its targeted action, it is well tolerated with a lower risk of severe toxicity compared to older antiviral medications.
Interaction of Anvimo 240mg Tablet with other drugs
Serious drug interactions can alter the effectiveness of Anvimo 240mg Tablet or increase the risk of side effects. Patients should inform their doctor about all medications, including herbal and over-the-counter drugs, before starting this medication.
Notable Drug Interactions:
- Immunosuppressants (e.g., Cyclosporine, Tacrolimus, Sirolimus): Letermovir can increase blood levels of these drugs, requiring dose adjustments.
- Statins (e.g., Simvastatin, Atorvastatin): Increased risk of myopathy or rhabdomyolysis when taken together. Avoid co-administration or monitor closely.
- Anticonvulsants (e.g., Phenytoin, Carbamazepine): May reduce Anvimo 240mg Tablet effectiveness, requiring alternative options.
- Rifampin and St. John’s Wort: These reduce drug efficacy and should be avoided.
- Oral Contraceptives: Letermovir may lower the effectiveness of hormonal birth control, necessitating additional contraceptive methods.
Always consult a doctor before combining this medication with others.
More Information about Anvimo 240mg Tablet
- Keep Anvimo 240mg Tablet at room temperature (20-25°C), away from moisture and direct sunlight.
- Do not double-dose.
- Seek immediate medical attention if an overdose occurs. Symptoms may include severe nausea or irregular heartbeat.
How to consume Anvimo 240mg Tablet
The usual recommended dosage of Anvimo 240mg Tablet for CMV prophylaxis is 480 mg once daily. However, if taken in combination with cyclosporine, the dose is reduced to 240 mg daily to prevent excessive drug levels. This medication is available in oral tablets and intravenous (IV) infusion forms. Oral tablets should be swallowed whole with or without food, while the IV infusion must be administered under medical supervision to ensure proper dosing and monitoring.
Safety Advice for Anvimo 240mg Tablet
Breast Feeding
It is unknown whether Anvimo 240mg Tablet passes into breast milk. A healthcare provider should assess whether to discontinue breastfeeding or the medication.
Alcohol
Alcohol can increase liver toxicity and should be avoided during treatment.
Liver
Patients with severe liver impairment should use caution, as Anvimo 240mg Tablet is metabolised in the liver. Dose adjustments may be required.
Lungs
No major respiratory effects have been reported. Patients with existing lung conditions can take Anvimo 240mg Tablet under medical guidance.
Driving
Anvimo 240mg Tablet does not impair alertness or cognitive function. Patients can safely drive and operate machinery unless experiencing dizziness.
Pregnancy
There is limited human data on Anvimo 240mg Tablet during pregnancy. It should only be used if the benefits outweigh the potential risks to the fetus.
Side Effects of Anvimo 240mg Tablet
Common Side Effects:
- Nausea
- Fatigue
- Headache
- Diarrhea
- Abdominal pain
Serious Side Effects:
- Irregular heartbeat
- Swelling in legs or feet
- Unexplained bleeding or bruising
- Severe allergic reactions (rash, breathing difficulty)
Word of Advice
Patients prescribed Anvimo 240mg Tablet should take it regularly to prevent CMV-related complications post-transplant. Always inform your doctor of any medications or supplements being taken to prevent harmful interactions. Missing doses can reduce the effectiveness of CMV prevention. Additionally, regular liver function tests may be required in certain patients.
FAQs about Anvimo 240mg Tablet
Q1.
What is Anvimo 240mg Tablet used for?
Anvimo 240mg Tablet is used to prevent cytomegalovirus (CMV) infection in adult patients who have received an allogeneic hematopoietic stem cell transplant (HSCT). Patients who are CMV-seropositive are at a higher risk of CMV reactivation, which can lead to severe complications. This medication helps lower the chances of CMV-related diseases by inhibiting viral replication. It is prescribed as a preventive measure and is not meant for treating active CMV infections. Doctors determine the treatment duration based on individual risk factors.
Q2.
How long should Anvimo 240mg Tablet be taken?
Anvimo 240mg Tablet is typically prescribed for up to 100 days following an HSCT procedure. However, the exact duration of treatment depends on a patient’s immune status and overall health condition. Some high-risk individuals may require extended therapy beyond 100 days, as per their doctor’s recommendation. Stopping the medication too early may increase the risk of CMV reactivation, which can lead to serious complications. Always follow your doctor’s instructions regarding treatment length.
Q3.
Can Anvimo 240mg Tablet be taken with cyclosporine?
Yes, Anvimo 240mg Tablet can be taken with cyclosporine, but the dose needs to be adjusted. When used together, the standard 480 mg daily dose of Anvimo 240mg Tablet is reduced to 240 mg daily to prevent excessive drug levels in the bloodstream. This adjustment is necessary to ensure safety and effectiveness, as cyclosporine affects the way Anvimo 240mg Tablet is metabolized. Patients should not modify their dosage without consulting their doctor, as incorrect dosing may impact CMV prevention. Regular monitoring is often required when these medications are used together.
Q4.
What should I do if I miss a dose?
If you miss a dose of Anvimo 240mg Tablet, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take two doses at once to make up for a missed dose, as this can increase the risk of side effects. Maintaining a consistent dosing routine is important for effective CMV prevention. If you frequently forget doses, consider setting a reminder or speaking with your doctor for advice.
Q5.
Is Anvimo 240mg Tablet safe for patients with kidney disease?
Yes, Anvimo 240mg Tablet is generally safe for patients with kidney disease, as it does not require dose adjustments in mild to moderate renal impairment. However, for patients undergoing dialysis, close monitoring is necessary, and dose modifications may be required. It is always important to inform your doctor about any pre-existing kidney conditions before starting this medication. While Anvimo 240mg Tablet is mainly metabolized by the liver, kidney function should still be assessed periodically. Patients with severe kidney impairment should take the medication under strict medical supervision
Fact Box of Anvimo 240mg Tablet
| Molecule name: Letermovir | Pharmacological class: Antiviral agent |
| Therapeutic class: CMV DNA terminase inhibitor | Indications: Prevention of CMV infection in HSCT patients |
References
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209939s011,209940s010lbl.pdf
- Daniels K, Clemmons A. Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation. https://pmc.ncbi.nlm.nih.gov/articles/PMC7517777/
- Lin A, Flynn J, DeRespiris L, Figgins B, Griffin M, Lau C, Proli A, Devlin SM, Cho C, Tamari R, Jakubowski AA, Papadopoulos EB, Giralt SA, Perales MA, Seo SK, Shaffer B. Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. https://pmc.ncbi.nlm.nih.gov/articles/PMC8441845/
Disclaimer
MrMed’s primary intention is to ensure that its consumers get accurate and trustworthy information that is reviewed by experts. The contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
Did you find this information helpful?
Author Details
Written By
Dr. Vijayalakshmi N.
BDS
Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 08 Aug 2026 | 06:05 AM (IST)
Want to know more?
Read Our Editorial Policy
